NXGN Stock Overview
Develops topical treatment for psoriasis. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nextgen Biomed Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.70 |
| 52 Week High | ₪1.70 |
| 52 Week Low | ₪0.60 |
| Beta | 0.85 |
| 11 Month Change | 2.19% |
| 3 Month Change | -20.16% |
| 1 Year Change | -51.75% |
| 33 Year Change | -95.18% |
| 5 Year Change | -55.06% |
| Change since IPO | -98.54% |
Recent News & Updates
Shareholder Returns
| NXGN | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | 8.0% | 0.5% | 0.3% |
| 1Y | -51.8% | -6.3% | 23.0% |
Return vs Industry: NXGN underperformed the IL Pharmaceuticals industry which returned -6.3% over the past year.
Return vs Market: NXGN underperformed the IL Market which returned 23% over the past year.
Price Volatility
| NXGN volatility | |
|---|---|
| NXGN Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IL Market | 7.3% |
| 10% least volatile stocks in IL Market | 2.9% |
Stable Share Price: NXGN's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: NXGN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 5 | Harel Hershtik | www.nextgen-biomed.com |
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group Com Ltd.
Nextgen Biomed Ltd Fundamentals Summary
| NXGN fundamental statistics | |
|---|---|
| Market cap | ₪6.77m |
| Earnings (TTM) | -₪13.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs NXGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXGN income statement (TTM) | |
|---|---|
| Revenue | ₪0 |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪0 |
| Other Expenses | ₪13.81m |
| Earnings | -₪13.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NXGN perform over the long term?
See historical performance and comparison